Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Nordstrom, Jeffrey L ^a   Gorlatov, Sergey ^a   Zhang, Wenjun ^a   Yang, Yinhua ^a   Huang, Ling ^a   Burke, Steve ^a   Li, Hua ^a   Ciccarone, Valentina ^a   Zhang, Tengfei ^a   Stavenhagen, Jeffrey ^a,b   Koenig, Scott ^a   Stewart, Stanford J ^a   Moore, Paul A ^a   Johnson, Syd ^a   Bonvini, Ezio ^a  

^a Analytical Sciences   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MGAH 22; MONOCLONAL ANTIBODY; RES 120; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FCGR3A PROTEIN, HUMAN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXPERIMENTAL NEOPLASM; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SPECIES; TOXICOKINETICS; TRANSGENICS; WILD TYPE; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; MACACA FASCICULARIS; METABOLISM; NEOPLASM; PROTEIN BINDING; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASMS; PROTEIN BINDING; RECEPTOR, ERBB-2; RECEPTORS, IGG;

EID: 82255167636     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3069     Document Type: Article

References (50)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
5. Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X, 20728210.
6. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847. 10.1200/JCO.2009.22.1507, 19884552.
7. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446. 10.1038/74704, 10742152.
8. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006, 94:259-267. 10.1038/sj.bjc.6602930, 2361112, 16404427.
9. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da PG, Zambelli A, Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655. 10.1158/1078-0432.CCR-04-0225, 15355889.
10. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, Costa A, Fagnoni FF. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007, 67:11991-11999. 10.1158/0008-5472.CAN-07-2068, 18089830.
11. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957, 18347005.
12. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-3718. 10.1200/JCO.2006.08.8021, 17704420.
13. Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sabourin JC, Boissiere-Michot F. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27:1122-1129. 10.1200/JCO.2008.18.0463, 19164213.
14. Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010, 46:1829-1834. 10.1016/j.ejca.2010.03.017, 20418097.
15. Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, Morreau H, van der Burg SH, Guchelaar HJ, van HT. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011, 17:5668-5673. 10.1158/1078-0432.CCR-11-0239, 21788356.
16. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947. 10.1200/JCO.2003.05.013, 12975461.
17. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758. 10.1182/blood.V99.3.754, 11806974.
18. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1547-1552. 10.1136/ard.2008.096982, 18930989.
19. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, Kelley B, Hymowitz S, Daniel D, Meng G, Ashkenazi A. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011, 19:101-113. 10.1016/j.ccr.2010.11.012, 21251615.
20. Sullivan KE, Jawad AF, Piliero LM, Kim N, Luan X, Goldman D, Petri M. Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. Rheumatology (Oxford) 2003, 42:446-452.
21. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, Fukazawa T, Jansen MD, Hashimoto H, van De Winkel JG, Kallenberg CG, Tokunaga K. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002, 46:1242-1254. 10.1002/art.10257, 12115230.
22. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47. 10.1038/nri2206, 18064051.
23. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89:4285-4289. 10.1073/pnas.89.10.4285, 49066, 1350088.
24. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv Enzyme Regul 2008, 48:152-164. 10.1016/j.advenzreg.2007.11.011, 18177741.
25. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007, 67:8882-8890. 10.1158/0008-5472.CAN-07-0696, 17875730.
26. Code of Federal Regulations, Title 9, Animals and Animal Products. , http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&tpl=/ecfrbrowse/Title09/9cfr2_main_02.tpl
27. National Research Council, Institute of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals 1996, Washington DC: National Academy Press, National Research Council, Institute of Laboratory Animal Resources.
28. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004, 3:1585-1592.
29. Rogers KA, Scinicariello F, Attanasio R. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J Immunol 2006, 177:3848-3856.
30. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23:41-51. 10.1016/j.immuni.2005.05.010, 16039578.
31. Mancardi DA, Iannascoli B, Hoos S, England P, Daeron M, Bruhns P. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008, 118:3738-3750. 10.1172/JCI36452, 2571035, 18949059.
32. Asada S, Choi Y, Yamada M, Wang SC, Hung MC, Qin J, Uesugi M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc Natl Acad Sci USA 2002, 99:12747-12752. 10.1073/pnas.202162199, 130531, 12242338.
33. Perussia B, Ravetch JV. Fc gamma RIII (CD16) on human macrophages is a functional product of the Fc gamma RIII-2 gene. Eur J Immunol 1991, 21:425-429. 10.1002/eji.1830210226, 1825635.
34. Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC. Herceptin. Handb Exp Pharmacol 2008, 181:183-219. 10.1007/978-3-540-73259-4_9, 18071947.
35. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006, 55:717-727. 10.1007/s00262-005-0058-x, 16151804.
36. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010, 70:4481-4489. 10.1158/0008-5472.CAN-09-3704, 20484044.
37. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006, 103:4005-4010. 10.1073/pnas.0508123103, 1389705, 16537476.
38. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008, 7:2517-2527. 10.1158/1535-7163.MCT-08-0201, 18723496.
39. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005, 11:2327-2336. 10.1158/1078-0432.CCR-04-2263, 15788684.
40. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, . American Society of Clinical Oncology/College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43. American Society of Clinical Oncology/College of American Pathologists.
41. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-26740. 10.1074/jbc.M202069200, 11986321.
42. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, Bowen K, Steeber DA, Haas KM, Poe JC, Tedder TF. Mouse CD20 expression and function. Int Immunol 2004, 16:119-129. 10.1093/intimm/dxh009, 14688067.
43. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005, 115:2914-2923. 10.1172/JCI24772, 1201664, 16167082.
44. Desai DD, Harbers SO, Flores M, Colonna L, Downie MP, Bergtold A, Jung S, Clynes R. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 2007, 178:6217-6226.
45. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, Steinman RM, Ravetch JV, Dhodapkar MV. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 2005, 102:2910-2915. 10.1073/pnas.0500014102, 549508, 15703291.
46. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000, 18:739-766. 10.1146/annurev.immunol.18.1.739, 10837074.
47. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007, 25:555-561. 10.1038/nbt1303, 17483842.
48. Cresti N, Jamieson D, Verrill MW, Pinkilgton M, Boddy AV. Fc{gamma}-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab. ASCO Meeting Abstracts 2011, 29:565.
49. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68:9280-9290. 10.1158/0008-5472.CAN-08-1776, 19010901.
50. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011, 29:398-405. 10.1200/JCO.2010.29.5865, 21172893.